How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,855 results for

Imiquimod

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Imiquimod (Zyclara) - actinic keratosis

Imiquimod (Zyclara) - actinic keratosis 1 Published 11 November 2019 1 SMC2211 imiquimod 3.75% cream (Zyclara®) Meda Pharmaceuticals 04 October 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission imiquimod (Zyclara ® ) is accepted for restricted use within NHSScotland. Indication (...) or balding scalp achieved complete clearance when treated with imiquimod 3.75% cream compared with vehicle. Chairman Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate. 1 Dosing Information Up to two sachets of imiquimod 3.75

2019 Scottish Medicines Consortium

2. Imiquimod for the Treatment of Actinic Keratosis: A Review of Clinical and Cost-Effectiveness

Imiquimod for the Treatment of Actinic Keratosis: A Review of Clinical and Cost-Effectiveness Imiquimod for the Treatment of Actinic Keratosis: A Review of Clinical and Cost-Effectiveness | CADTH.ca Find the information you need Imiquimod for the Treatment of Actinic Keratosis: A Review of Clinical and Cost-Effectiveness Imiquimod for the Treatment of Actinic Keratosis: A Review of Clinical and Cost-Effectiveness Published on: September 15, 2017 Project Number: RC0929-000 Product Line: Research (...) Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of imiquimod for the treatment of actinic keratosis? What is the cost-effectiveness of imiquimod for the treatment of actinic keratosis? Key Message The three included systematic reviews showed that in patients with actinic keratosis (AK), treatment with imiquimod (IMQ) appeared to be better than placebo with respect to complete clearance.Few primary studies were available

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

3. Imiquimod for the Treatment of Genital Warts: A Review of Clinical Effectiveness and Cost-Effectiveness

Imiquimod for the Treatment of Genital Warts: A Review of Clinical Effectiveness and Cost-Effectiveness Imiquimod for the Treatment of Genital Warts: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Imiquimod for the Treatment of Genital Warts: A Review of Clinical Effectiveness and Cost-Effectiveness Imiquimod for the Treatment of Genital Warts: A Review of Clinical Effectiveness and Cost-Effectiveness Published on: September 25, 2017 Project (...) Number: RC0930-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of imiquimod for the treatment of genital warts? What is the cost-effectiveness of imiquimod for the treatment of genital warts? Key Message Evidence from systematic reviews with low quality included studies suggests that overall for patients with anogenital warts (AGW) compared to placebo, treatment with imiquimod (IMQ) is associated

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

4. Allergen immunotherapy in the setting of Imiquimod treatment

Allergen immunotherapy in the setting of Imiquimod treatment Allergen immunotherapy in the setting of Imiquimod treatment ') Cookie Notice This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our for more details. OK Menu Search Main navigation Utility navigation / Search navigation Search Search AAAAI Breadcrumb navigation ▸ ▸ Allergen immunotherapy in the setting of Imiquimod treatment | Allergen immunotherapy in the setting of Imiquimod (...) treatment Q: 5/13/2020 A 40 year-old lady who has suffered with skin cancer for which is being treated with aldara topical, (Imiqimod) she wishes to go on immunotherapy for environmental allergies, is it safe to use the allergy serum while she is on this topical treatment or is it contraindicated? A: Imiquimod is a topical immunomodulatory therapy with TLR7 agonist-like activity. Very low serum concentrations have been found in patients who are using Imiquimod and it is thought to have minimal skin

2020 American Academy of Allergy, Asthma & Immunology - Ask the Expert

5. Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: results from a multicentre, randomised, phase II trial (RT3VIN) Full Text available with Trip Pro

Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: results from a multicentre, randomised, phase II trial (RT3VIN) To compare the recurrence rates after complete response to topical treatment with either cidofovir or imiquimod for vulval intraepithelial neoplasia (VIN) 3.A prospective, open, randomised multicentre trial.32 general hospitals located in Wales and England.180 patients were randomised consecutively between 21 October 2009 and 11 January (...) 2013, 89 to cidofoovir (of whom 41 completely responded to treatment) and 91 to imiquimod (of whom 42 completely responded to treatment).After 24 weeks of treatment, complete responders were followed up at 6-monthly intervals for 24 months. At each visit, the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was assessed and any new lesions were biopsied for histology.Time to histologically confirmed disease recurrence (any grade of VIN).The median length of follow up was 18.4 months

2018 EvidenceUpdates

6. Surgery versus combined treatment with curettage and imiquimod for nodular basal cell carcinoma: One-year results of a noninferiority, randomized, controlled trial. (Abstract)

Surgery versus combined treatment with curettage and imiquimod for nodular basal cell carcinoma: One-year results of a noninferiority, randomized, controlled trial. Nodular basal cell carcinoma (nBCC) is mostly treated with surgical excision. Interest in minimally invasive treatment of these low-risk tumors is increasing. We assessed the effectiveness of nBCC treatment with curettage and imiquimod cream compared with surgical excision.Patients with nBCC included in this randomized, controlled (...) noninferiority trial were randomly assigned to either a curettage and imiquimod cream group or a surgical excision group. The primary endpoint was the proportion of patients free from treatment failure 1 year after the end of treatment. A prespecified noninferiority margin of 8% was used. A modified intention-to-treat and a per-protocol analysis was performed (ClinicalTrials.gov identifier NCT02242929).One hundred forty-five patients were randomized: 73 to the curettage and imiquimod cream group and 72

2020 Journal of American Academy of Dermatology

7. Poly(ADP-ribose) polymerase-1 depletion enhances the severity of inflammation in an imiquimod-induced model of psoriasis. Full Text available with Trip Pro

Poly(ADP-ribose) polymerase-1 depletion enhances the severity of inflammation in an imiquimod-induced model of psoriasis. Poly(ADP-ribose) polymerase-1 (PARP1) is a pro-inflammatory protein, whose pro-inflammatory properties were demonstrated in human. The pro-inflammatory properties of PARP1 were shown in Th1- and Th2-mediated inflammatory pathologies, but not Th17-mediated inflammation. Thus, we studied the role of PARP1 in the imiquimod-induced model of psoriasis. To our surprise (...) , in imiquimod-induced psoriasis, PARP1 acted as an anti-inflammatory factor and its genetic deletion exacerbated symptoms. We showed that in the absence of PARP1, the epidermis thickened and the number of TUNEL-positive cells decreased in the epidermis. These data indicate programmed cell death is decreased in keratinocytes. Changes in involucrin expression suggest that keratinocyte differentiation is hampered. Furthermore, epidermal expression of IL6 increased in the psoriasiform lesions of PARP1 knockout

2020 Experimental Dermatology

8. The severity of imiquimod-induced mouse skin inflammation is independent of endogenous IL-38 expression. Full Text available with Trip Pro

The severity of imiquimod-induced mouse skin inflammation is independent of endogenous IL-38 expression. The IL-1 cytokine family includes eleven members, among which Il-36α, β and γ, IL-36Ra and IL-38. The IL-36 cytokines are involved in the pathogenesis of psoriasis. IL-38 is also expressed in the skin and was previously proposed to act as an IL-36 antagonist. In this study, we thus examined expression and function of Il-38 in a mouse model of imiquimod (IMQ)-induced skin inflammation. Il-38

2018 PLoS ONE

9. Correction: PAMs ameliorates the imiquimod-induced psoriasis-like skin disease in mice by inhibition of translocation of NF-κB and production of inflammatory cytokines. Full Text available with Trip Pro

Correction: PAMs ameliorates the imiquimod-induced psoriasis-like skin disease in mice by inhibition of translocation of NF-κB and production of inflammatory cytokines. [This corrects the article DOI: 10.1371/journal.pone.0176823.].

2018 PLoS ONE

10. Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment. Full Text available with Trip Pro

Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment. Lentigo maligna (LM) is treated to prevent progression to lentigo maligna melanoma (LMM). Surgery is the gold standard but an alternative treatment is off-label topical imiquimod. The aim of this study was to evaluate the effectiveness of 5% topical imiquimod treatment for lentigo maligna. In the period 2007-2017 57 patients with lentigo maligna were treated with off-label topical imiquimod once daily for 12 weeks. Complete (...) clinical clearance was observed in 48 patients (84.2%) and partial clearance in 3 patients (5.3%). Three patients (5.3%) showed no response and another 3 patients (5.3%) stopped treatment due to side-effects. After 4.5 years during follow-up one patient developed a lentigo maligna melanoma which was subsequently excised. Treatment with topical imiquimod resulted in complete clearance of lentigo maligna in 48 out of 57 patients (84.2%). Topical imiquimod is an acceptable treatment option for patients

2019 Acta Dermato-Venereologica

11. Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials. Full Text available with Trip Pro

Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials. Actinic keratosis (AK) is an early in situ epidermal cancer which can progress to invasive squamous cell carcinoma (SCC). Imiquimod 5% cream (IMIQ) and diclofenac 3% gel (DIC) are frequently used to treat AK; however, their long-term effects following repeated treatment cycles have never been compared.To compare IMIQ and DIC

2019 Journal of the European Academy of Dermatology and Venereology Controlled trial quality: predicted high

12. Anti-IL-17A and IL-23p19 antibodies but not anti-TNFα antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis. Full Text available with Trip Pro

Anti-IL-17A and IL-23p19 antibodies but not anti-TNFα antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis. Psoriasis is a chronic inflammatory skin disease. Anti-TNFα, IL-17A and IL-23p19 antibodies are effective for psoriasis. However, the contribution of regulatory T cells (Treg) in their effectiveness remains to be elucidated.We investigated the effects of TNFα, IL-17A and IL-23p19 inhibition on Tregs (...) in imiquimod-induced psoriasiform dermatitis.Psoriasiform dermatitis was induced by imiquimod application on murine shaved back skin for six days. Mice were treated with anti-TNFα, IL-17A or IL-23p19 monoclonal antibodies every other day from one day before imiquimod application.Administration of anti-TNFα, IL-17A or IL-23p19 antibodies improved the clinical score and downregulated Th17-related cytokines and chemokines, while IL-23p19 antibodies upregulated IL-10 mRNA expression. Anti-IL-17A or IL-23p19

2019 Journal of dermatological science

13. "Imiquimod acts synergistically with BMP9 via the Notch pathway as an osteoinductive agent in vitro". (Abstract)

"Imiquimod acts synergistically with BMP9 via the Notch pathway as an osteoinductive agent in vitro". Autologous bone grafts used for surgical reconstruction are limited by infection or insufficient supply of host material. Experimental agents that promote differentiation of stem cells into mature bone are currently being studied for future use in the repair of bone defects. We hypothesized that Imiquimod, a synthetic immune response modifier, increases Notch pathway gene expression and acts (...) synergistically with BMP9 to induce differentiation of mesenchymal stem cells (MSCs) toward an osteogenic phenotype.Alkaline phosphatase (ALP) activity was used to assess osteogenic potential of cultured mouse multipotent adipose-derived cells (iMADs) treated with 0, 4, 6, and 8 ∞g/mL of Imiquimod with and without BMP9. Adenoviral vectors expressing human-BMP9 and a dominant-negative mutant of mouse Notch1 were used to assess BMP9 and Notch blockade, on osteogenic activity, respectively. Expression of Notch

2019 Plastic and reconstructive surgery

14. A distinct pre-treatment immune gene signature in lentigo maligna is associated with imiquimod response. (Abstract)

A distinct pre-treatment immune gene signature in lentigo maligna is associated with imiquimod response. Lentigo Maligna (LM) is a common subtype of in-situ melanoma on chronically sun-exposed skin, particularly the head and neck of older patients. Whilst surgery is the standard treatment, there is associated morbidity and options such as imiquimod cream or radiotherapy may be used if surgery is refused or inappropriate. Complete response rates following imiquimod treatment are variable (...) in the literature. The aim of this study was to evaluate the host immune response both prior to and following treatment with imiquimod to better identify likely responders. Paired pre- and post-imiquimod treatment specimens were available for 27 patients. Patients were treated with imiquimod 5 days per week for 12 weeks; at 16 weeks, lesions were excised for histological assessment. 16 of the 27 patients were responders and 11 failed to clear the disease. PDL1 protein expression was increased, accompanied

2019 Journal of Investigative Dermatology

15. Acupuncture Needling, Electroacupuncture, and Fire Needling Improve Imiquimod-Induced Psoriasis-Like Skin Lesions through Reducing Local Inflammatory Responses. Full Text available with Trip Pro

Acupuncture Needling, Electroacupuncture, and Fire Needling Improve Imiquimod-Induced Psoriasis-Like Skin Lesions through Reducing Local Inflammatory Responses. Psoriasis is a common autoimmune disease. Acupuncture-related techniques have been widely used to treat psoriasis since its ability to engage neuronal function, the immune system, and other systems is well documented. This study aimed to investigate and compare the effects of three common acupuncture-related techniques in psoriasis-like (...) skin inflammatory responses and explore the possible involved mechanisms. Imiquimod (IMQ)-induced psoriasis-like mice were treated with acupuncture needling, electroacupuncture, or fire acupuncture. Methotrexate (MTX) was applied as a positive control. Scoring by the psoriasis area and severity index (PASI) evaluated skin lesion changes. Keratinocyte proliferation and inflammatory cell infiltration were investigated using pathological staining. The secretion levels of inflammatory cytokines were

2019 Evidence-based Complementary and Alternative Medicine (eCAM)

16. Photothermal therapy enhanced the effectiveness of imiquimod against refractory cutaneous warts through boosting immune responses. (Abstract)

Photothermal therapy enhanced the effectiveness of imiquimod against refractory cutaneous warts through boosting immune responses. Refractory cutaneous warts are difficult to eliminate. In situ photo-immunotherapy (ISPI) is an innovative treatment concept combining local photothermal therapy (PTT) and topical immunotherapy using imiquimod. To compare the efficacy of ISPI vs topical imiquimod alone, a prospective randomized controlled trial was performed with patients suffering from refractory (...) cutaneous warts. In both groups, approximately 50% of the skin surface containing warts was treated for 6 weeks. On the basis of topical imiquimod, ISPI includes an additional 808 nm laser irradiation. Treatment response, temperatures during irradiation and histopathologic examination were evaluated. The complete response rate in the ISPI-group (22/36, 61.1%) was significantly higher than in the imiquimod alone group (11/34, 32.4%). In the ISPI-group, the mean maximum temperature was 44.5 ± 5.1°C

2019 Journal of biophotonics Controlled trial quality: uncertain

17. Imiquimod 3.75% for field-directed therapy of actinic keratosis: results of a prospective case-series study in Greece. Full Text available with Trip Pro

Imiquimod 3.75% for field-directed therapy of actinic keratosis: results of a prospective case-series study in Greece. Imiquimod 3.75% is a field-directed treatment for actinic keratosis that can detect and treat clinical and subclinical lesions across an entire sun-exposed field. The detection of subclinical lesions is evidenced by an increase in lesions to the maximum lesion count during treatment (Lmax ). We report clinical outcomes for the first 15 patients treated with imiquimod 3.75 (...) % in daily clinical practice in Greece.Fifteen patients with actinic keratosis lesions were treated with imiquimod 3.75% in an outpatient setting in two 2-week treatment cycles separated by a 2-week treatment-free interval. Actinic keratosis lesions were counted before treatment, at the end of the first treatment cycle (Week 2; Lmax ), and 2 weeks after the second treatment cycle (Week 8). Local skin reactions (LSR) were also evaluated at Weeks 2 and 8.The median baseline actinic keratosis lesion count

2019 International Journal of Dermatology

18. Cis-khellactone inhibited the proinflammatory macrophages via promoting autophagy to ameliorate imiquimod-induced psoriasis. Full Text available with Trip Pro

Cis-khellactone inhibited the proinflammatory macrophages via promoting autophagy to ameliorate imiquimod-induced psoriasis. Psoriasis is a chronic inflammatory skin disease with unresolved pathogenesis. Studies on the pathogenesis of psoriasis have been extensively carried out, but treatments are still not satisfactory. In this study, we found improvement after treatment with cis-khellactone, a small molecular natural product, in imiquimod-challenged C57BL/6 mice. cis-Khellactone clearly (...) modulated macrophage function and phenotype by inducing autophagy to ameliorate imiquimod-induced psoriasis in mice. Our research provides an effective strategy for the treatment of psoriasis.Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

2019 Journal of Investigative Dermatology

19. Impact of smoking on imiquimod response in patients with vulval intraepithelial neoplasia. (Abstract)

Impact of smoking on imiquimod response in patients with vulval intraepithelial neoplasia. Vulval intraepithelial neoplasia (VIN) is a precancerous condition that may progress to invasive malignancy. VIN is associated with human papillomavirus (HPV) infection in most cases, and with inflammatory skin disorders in a smaller proportion of patients. Treatment of VIN has traditionally been surgical excision; however, topical treatments, including imiquimod cream, are becoming increasingly used (...) . Patient factors influencing response to imiquimod therapy, in particular smoking, have not yet been published.To assess the impact of smoking and other patient characteristics that may influence the treatment response to topical imiquimod for VIN.This was a retrospective cohort study of 46 women treated with topical imiquimod for VIN in a single centre dermatology unit from January 2011 to July 2017.Complete clinical resolution of VIN was observed in 28 of 46 patients (61%), but was significantly

2019 Clinical & Experimental Dermatology

20. Imiquimod-induced psoriasis in mice depends on the IL-17 signaling of keratinocytes. Full Text available with Trip Pro

Imiquimod-induced psoriasis in mice depends on the IL-17 signaling of keratinocytes. The pathology of psoriasis strongly depends on IL-17A. Monoclonal antibodies blocking either the cytokine or its receptor are among the most efficient treatments for psoriatic patients. Keratinocytes can be activated upon exposure to IL-17A and tumor necrosis factor-α and secrete secondary cytokines and chemokines in the inflamed skin. In psoriasis and its imiquimod-induced mouse model, a strong skin (...) development. Only deletion of this receptor in keratinocytes reflected the full-body deletion of IL-17RA, resulting in strongly reduced dermatitis development. Imiquimod treatment of those IL-17 signaling-deficient mice maintained high monocytic infiltration but failed to attract neutrophils into the skin. We conclude that keratinocytes are a critical cellular target for IL-17A-mediated neutrophil attraction and psoriasis development.Copyright © 2019 The Authors. Published by Elsevier Inc. All rights

2019 Journal of Investigative Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>